发展历程
Built with full chain capability.
Innovative biopharmaceutical enterprises.
Drug discovery capability.
Drug development capability.
Construction of Nanjing pilot production workshop.
Initiating ONC-392 Phase III clinical trial.
ONC-782 entered the registered clinical trial phase.
Completed Series B financing.
Form independent innovative products with independent intellectual property rights.
AI-071 project enters clinical phase.
The ONC-392 program entered Phase II clinical trials.
Completed A+ round of financing.
Completed the acquisition of Suzhou Stanway.
Completed ONC-392 Phase I clinical trial.
Completed the merger and reorganization of Suzhou Angkang.
Obtained ONC-392 clinical approval.
Set up Guangzhou R&D laboratory.
Completed preclinical development of ONC-392.
